Enlivex Ltd. (ENLV) Form 6-K — Nov 2, 2026
Enlivex announced favorable 12-month topline data from the Phase IIa stage of its Phase I/IIa trial (ENX-CL-05-001) of Allocetra™ in moderate to severe knee osteoarthritis. In patients aged 64+, 79.2% of Allocetra™ patients achieved a clinically meaningful response versus 47.6% on placebo at 12 months (p=0.027), consistent with benefits seen at 3 and 6 months, indicating a durable effect from a single three-injection treatment cycle. Safety through 12 months was favorable, with no treatment-related serious adverse events. The data will be presented at the ACR Convergence on November 8, 2026, in a poster by Prof.
Key figures
- Us knee oa patients
- more than 32 million
- Womac pain 12mo diff
- -12.2 points (p=0.113)
- P value 3mo responders
- 0.019
- P value 6mo responders
- 0.168
- P value 12mo responders
- 0.027
- Placebo responders 12mo
- 47.6%
- Womac function 12mo diff
- -13.1 points (p=0.067)
- Allocetra responders 12mo
- 79.2%
- Patients randomized phase iia
- 134
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.